Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
ELUTIA INC (ELUT) Stock Price & Overview
NASDAQ:ELUT • US05479K1060
Current stock price
1.01 USD
-0.01 (-0.98%)
At close:
1.05 USD
+0.04 (+3.96%)
After Hours:
The current stock price of ELUT is 1.01 USD. Today ELUT is down by -0.98%. In the past month the price decreased by -13.68%. In the past year, price decreased by -50.49%.
ELUT Key Statistics
52-Week Range0.5 - 2.64
Current ELUT stock price positioned within its 52-week range.
1-Month Range0.9901 - 1.2052
Current ELUT stock price positioned within its 1-month range.
- Market Cap
- 43.208M
- P/E
- 0.95
- Fwd P/E
- N/A
- EPS (TTM)
- 1.06
- Dividend Yield
- N/A
ELUT Stock Performance
Today
-0.98%
1 Week
-5.61%
1 Month
-13.68%
3 Months
-3.81%
Longer-term
6 Months +11.06%
1 Year -50.49%
2 Years -68.92%
3 Years N/A
5 Years N/A
10 Years N/A
ELUT Stock Chart
ELUT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ELUT. When comparing the yearly performance of all stocks, ELUT is a bad performer in the overall market: 89.25% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
ELUT Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ELUT. ELUT has an average financial health and profitability rating.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ELUT Earnings
On March 11, 2026 ELUT reported an EPS of 1.48 and a revenue of 3.27M. The company beat EPS expectations (1136.41% surprise) and missed revenue expectations (-2.82% surprise).
Next Earnings DateMay 7, 2026
Last Earnings DateMar 11, 2026
PeriodQ4 / 2025
EPS Reported$1.48
Revenue Reported3.271M
EPS Surprise 1,136.41%
Revenue Surprise -2.82%
ELUT Forecast & Estimates
7 analysts have analysed ELUT and the average price target is 5.1 USD. This implies a price increase of 404.95% is expected in the next year compared to the current price of 1.01.
For the next year, analysts expect an EPS growth of -151.96% and a revenue growth -36.51% for ELUT
Analysts
Analysts82.86
Price Target5.1 (404.95%)
EPS Next Y-151.96%
Revenue Next Year-36.51%
ELUT Index Membership
ELUT is currently included in the following stock indexes tracked on ChartMill.
ELUT Financial Highlights
Over the last trailing twelve months ELUT reported a non-GAAP Earnings per Share(EPS) of 1.06. The EPS increased by 142.91% compared to the year before.
Income Statements
Revenue(TTM)18.89M
Net Income(TTM)53.38M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 282.63% | ||
| ROA | 85.61% | ||
| ROE | 192.9% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%669.23%
Sales Q2Q%-40.18%
EPS 1Y (TTM)142.91%
Revenue 1Y (TTM)-39.21%
ELUT Ownership
Ownership
Inst Owners33.12%
Shares42.78M
Float34.54M
Ins Owners3.11%
Short Float %0.36%
Short Ratio0.93
ELUT Industry Overview
ELUT operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
ELUT Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ELUT
Company Profile
Elutia, Inc. is a biotechnology company, which engages in the provision of biologic products to improve compatibility between medical devices and the patients who need them. The company is headquartered in Silver Spring, Maryland and currently employs 51 full-time employees. The company went IPO on 2020-10-08. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. The company is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
Company Info
IPO: 2020-10-08
ELUTIA INC
12510 Prosperity Drive, Suite 370
Silver Spring MARYLAND US
Employees: 26
Phone: 13026365400
ELUTIA INC / ELUT FAQ
Can you describe the business of ELUTIA INC?
Elutia, Inc. is a biotechnology company, which engages in the provision of biologic products to improve compatibility between medical devices and the patients who need them. The company is headquartered in Silver Spring, Maryland and currently employs 51 full-time employees. The company went IPO on 2020-10-08. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. The company is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
Can you provide the latest stock price for ELUTIA INC?
The current stock price of ELUT is 1.01 USD. The price decreased by -0.98% in the last trading session.
Does ELUTIA INC pay dividends?
ELUT does not pay a dividend.
What is the ChartMill technical and fundamental rating of ELUT stock?
ELUT has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How many employees does ELUTIA INC have?
ELUTIA INC (ELUT) currently has 26 employees.
What is the market capitalization of ELUT stock?
ELUTIA INC (ELUT) has a market capitalization of 43.21M USD. This makes ELUT a Nano Cap stock.